141 related articles for article (PubMed ID: 12270732)
1. Molecular mechanisms of B-lymphocyte transformation by Epstein-Barr virus.
Bishop GA; Busch LK
Microbes Infect; 2002 Jul; 4(8):853-7. PubMed ID: 12270732
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus: 40 years on.
Young LS; Rickinson AB
Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
[TBL] [Abstract][Full Text] [Related]
3. B cells under influence: transformation of B cells by Epstein-Barr virus.
Küppers R
Nat Rev Immunol; 2003 Oct; 3(10):801-12. PubMed ID: 14523386
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of B-Cell Oncogenesis Induced by Epstein-Barr Virus.
Saha A; Robertson ES
J Virol; 2019 Jul; 93(13):. PubMed ID: 30971472
[TBL] [Abstract][Full Text] [Related]
5. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
6. Cell transformation induced by Epstein-Barr virus--living dangerously.
Rowe M
Semin Cancer Biol; 2001 Dec; 11(6):403-5. PubMed ID: 11669601
[No Abstract] [Full Text] [Related]
7. Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors.
Chen X; Kamranvar SA; Masucci MG
Oncogene; 2016 Jul; 35(29):3807-16. PubMed ID: 26592445
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.
Saha A; Robertson ES
Clin Cancer Res; 2011 May; 17(10):3056-63. PubMed ID: 21372216
[TBL] [Abstract][Full Text] [Related]
9. Dithiocarbamates and viral IL-10 collaborate in the immortalization and evasion of immune response in EBV-infected human B lymphocytes.
Irons RD; Le AT
Chem Biol Interact; 2008 Mar; 172(1):81-92. PubMed ID: 18163983
[TBL] [Abstract][Full Text] [Related]
10. Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses.
Lacoste V; Judde JG; Bestett G; Cadranel J; Antoine M; Valensi F; Delabesse E; Macintyre E; Gessain A
Leuk Lymphoma; 2000 Jul; 38(3-4):401-9. PubMed ID: 10830748
[TBL] [Abstract][Full Text] [Related]
11. Current Trends and Alternative Scenarios in EBV Research.
Minarovits J; Niller HH
Methods Mol Biol; 2017; 1532():1-32. PubMed ID: 27873264
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
Aguirre AJ; Robertson ES
J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735
[TBL] [Abstract][Full Text] [Related]
13. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
Tanner JE; Alfieri C
Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin's lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules.
Kasprzak A; Spachacz R; Wachowiak J; Stefanska K; Zabel M
Folia Histochem Cytobiol; 2007; 45(3):169-79. PubMed ID: 17951165
[TBL] [Abstract][Full Text] [Related]
15. NF-κB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas.
Vento-Tormo R; Rodríguez-Ubreva J; Lisio LD; Islam AB; Urquiza JM; Hernando H; López-Bigas N; Shannon-Lowe C; Martínez N; Montes-Moreno S; Piris MA; Ballestar E
Nucleic Acids Res; 2014; 42(17):11025-39. PubMed ID: 25200074
[TBL] [Abstract][Full Text] [Related]
16. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.
Miyauchi K; Urano E; Yoshiyama H; Komano J
Cancer Sci; 2011 Jun; 102(6):1236-41. PubMed ID: 21392167
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth.
Shannon-Lowe C; Baldwin G; Feederle R; Bell A; Rickinson A; Delecluse HJ
J Gen Virol; 2005 Nov; 86(Pt 11):3009-3019. PubMed ID: 16227222
[TBL] [Abstract][Full Text] [Related]
18. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas.
Finberg RW
Curr Opin Oncol; 2001 Sep; 13(5):349-53. PubMed ID: 11555711
[TBL] [Abstract][Full Text] [Related]
20. To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis.
Price AM; Luftig MA
PLoS Pathog; 2015 Mar; 11(3):e1004656. PubMed ID: 25790223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
